We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Photodynamic Therapy of Acne Vulgaris - a Randomized Blinded Controlled Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00206895
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : October 11, 2006
Information provided by:
Bispebjerg Hospital

Brief Summary:
The purpose of the study is to evaluated the efficacy and tolerability of methyl aminolevulinate and 5-aminolevulinic acid photodynamic therapy in patients with moderate to severe facial acne vulgaris in a randomized controlled and investigator blinded trial.

Condition or disease Intervention/treatment
Acne Vulgaris Procedure: Photodynamic therapy

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Study Start Date : November 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne
U.S. FDA Resources

Primary Outcome Measures :
  1. Lesion counts (non-inflammatory and inflammatory)
  2. Leeds Revised Acne Grading System

Secondary Outcome Measures :
  1. Pain
  2. Side effects

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:18 years or older, good health, more than 12 inflammatory facial acne lesions -

Exclusion Criteria:skin type VI, pregnant or lactating woman. Oral retinoid use within one year, systemic antibiotics within 1 month, topical acne treatment within 2 weeks.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00206895

Bispebjerg Hospital
Copenhagen, Copenhagen NV, Denmark, 2400
Sponsors and Collaborators
Bispebjerg Hospital
Study Director: Hans Christian Wulf, MD, Sci Bispebjerg Hospital

ClinicalTrials.gov Identifier: NCT00206895     History of Changes
Other Study ID Numbers: KF-01-177/04
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: October 11, 2006
Last Verified: October 2004

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases